Conjunctival provocation testing in a dose finding study with subcutaneous immunotherapy with grass  + mpl

The total symptom score (TSS) measured during conjunctival provocation testing (CPT) was used as primary endpoint of a Phase II study to evaluate the dose response for a subcutaneous immunotherapy (SCIT) product (1.0 ml) with modified allergen tyrosine adsorbate (MATA) and monophosphoryl lipid A (MPL) adjuvants developed for treatment of allergic rhinoconjunctivitis due to grass pollen [EudraCT 2017-000333-31]. Doses of 5100, 14400, 27600 and 35600 standardized units (SU) and placebo were evaluated.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: P109 Source Type: research